Back to Search
DAN LU, M.D., PH.D.
M.D., PH.D.
Anatomic Pathology & Clinical Pathology Physician
NPI: 1609135995IndividualAccepts Medicare
Specialties, Licenses & Credentials
Anatomic Pathology & Clinical Pathology PhysicianPrimary
Pathology — Anatomic Pathology & Clinical Pathology
Code: 207ZP0102X
280389(NY)
CMS Specialties
PrimaryPATHOLOGY
Education
OTHER
Class of 1994
Research & Publications (20)
Construction and production of an IgG-like tetravalent bispecific antibody for enhanced therapeutic efficacy.
PMID 19252849·Methods Mol Biol·2009
7-preclinical
REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis.
PMID 15907476·Cell·2005
7-preclinical
A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.
PMID 15757893·J Biol Chem·2005
7-preclinical
Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.
PMID 14576153·J Biol Chem·2004
8-other
The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
PMID 15120630·Biochem Biophys Res Commun·2004
8-other
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.
PMID 12917408·J Biol Chem·2003
8-other
Di-diabody: a novel tetravalent bispecific antibody molecule by design.
PMID 12969563·J Immunol Methods·2003
8-other
Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments.
PMID 12165442·J Immunol Methods·2002
7-preclinical
Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.
PMID 11774295·Int J Cancer·2002
8-other
Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
PMID 11585724·Cancer Res·2001
7-preclinical
Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies.
PMID 10799512·J Biol Chem·2000
8-other
A high voltage method for measuring low capacitance for tomography.
PMID 19485513·Rev Sci Instrum·2009
8-other
Growth hormone and prolactin in Andrias davidianus: cDNA cloning, tissue distribution and phylogenetic analysis.
PMID 19616001·Gen Comp Endocrinol·2010
7-preclinical
Intermediate outcomes of Ahmed glaucoma valve surgery in Asian patients with intractable glaucoma.
PMID 19648901·Eye (Lond)·2010
8-other
Silica coating magnetic nanoparticle-based silver enhancement immunoassay for rapid electrical detection of ricin toxin.
PMID 19631678·Toxicon·2010
4-observational
Mucinous adenocarcinoma as heterologous element in intermediately differentiated Sertoli-Leydig cell tumor of the ovary.
PMID 19674851·Pathol Res Pract·2010
5-case
Animal models of tracheal allotransplantation using vitrified cryopreservation.
PMID 19660277·J Thorac Cardiovasc Surg·2009
7-preclinical
Hydrogen peroxide induces the activation of the phospholipase C-gamma1 survival pathway in PC12 cells: protective role in apoptosis.
PMID 19657563·Acta Biochim Biophys Sin (Shanghai)·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1468 MADISON AVE BLDG RM15-265
NEW YORK, NY 10029 - Phone
- (212) 241-1822
Quick Facts
- NPI
- 1609135995
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 32
- Publications
- 20
Are you this provider?
Claim Your Profile